PUBLIC COMPANY
save$UTHRUNITED THERAPEUTICS Corp
$UTHR521.00-1.54%Silver Spring, MD, USupdated 5h ago
United Therapeutics Corporation is an American biotechnology company that develops pharmaceuticals and technologies related to organ transplantation, including xenotransplantation. Many of the company's products are focused towards lung disease and organ manufacturing. United Therapeutics is co-headquartered in Silver Spring, Maryland and Research Triangle Park, North Carolina, with additional facilities in Magog and Bromont, Quebec; Melbourne and Jacksonville, Florida; Blacksburg, Virginia; and Manchester, New Hampshire.
community read0 votes
pipeline
6
marketed
4
phase 3
2
catalysts ytd
5
approvals ytd
1
recalls ytd
0
Pipeline(6)
pipeline depth6 products
2Phase 34Marketed
Marketed
Remodulin
Pulmonary Arterial Hypertension
MarketedTyvaso DPI
Pulmonary Arterial Hypertension
Marketeddinutuximab
Neuroblastoma
Marketedtreprostinil diolamine ER
Pulmonary Arterial Hypertension
Phase 3ralinepag XR
Pulmonary Arterial Hypertension
Prostacyclin receptor
Phase 3treprostinil
Idiopathic Pulmonary Fibrosis
Prostacyclin receptor
Upcoming
Recent(90d)
earnings (2)
Active trials
- phase3Study of Ralinepag on Exercise Capacity by Cardiopulmonary Exercise Testing (CPET) in WHO Group 1 PH Subjects
- phase3Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease
- phase3Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
- N/AStudy on the Efficacy and Tolerance of a New Anti-regurgitation Infant Formula (STELLAR)
- —DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
- phase3A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients
- phase3Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
- phase3Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
Insider activity
source: SEC Form 4open-market buys + sells
- Apr 24, 26SELLPATUSKY CHRISTOPHER· −$1.66M↗
- Apr 23, 26SELLEDGEMOND JAMES· CFO AND TREASURER−$2.28M↗
- Apr 23, 26SELLROTHBLATT MARTINE A· Chairperson & CEO−$2.11M↗
- Apr 23, 26SELLEDGEMOND JAMES· CFO AND TREASURER−$1.90M↗
- Apr 23, 26SELLROTHBLATT MARTINE A· Chairperson & CEO−$1.67M↗
- Apr 23, 26SELLEDGEMOND JAMES· CFO AND TREASURER−$616K↗
- Apr 23, 26SELLROTHBLATT MARTINE A· Chairperson & CEO−$602K↗
- Apr 23, 26SELLROTHBLATT MARTINE A· Chairperson & CEO−$325K↗
- Apr 23, 26SELLEDGEMOND JAMES· CFO AND TREASURER−$308K↗
- Apr 23, 26SELLROTHBLATT MARTINE A· Chairperson & CEO−$299K↗
- Apr 23, 26SELLROTHBLATT MARTINE A· Chairperson & CEO−$207K↗
- Apr 23, 26SELLEDGEMOND JAMES· CFO AND TREASURER−$184K↗
- Apr 23, 26SELLEDGEMOND JAMES· CFO AND TREASURER−$159K↗
- Apr 23, 26SELLROTHBLATT MARTINE A· Chairperson & CEO−$140K↗
- Apr 23, 26SELLROTHBLATT MARTINE A· Chairperson & CEO−$82K↗
- Apr 23, 26SELLEDGEMOND JAMES· CFO AND TREASURER−$69K↗
- Apr 22, 26SELLROTHBLATT MARTINE A· Chairperson & CEO−$1.03M↗
- Apr 22, 26SELLROTHBLATT MARTINE A· Chairperson & CEO−$985K↗
- Apr 22, 26SELLROTHBLATT MARTINE A· Chairperson & CEO−$944K↗
- Apr 22, 26SELLROTHBLATT MARTINE A· Chairperson & CEO−$812K↗
🐶 Hiring Signal
next earnings Oct 28, 2026
News
- Tolerance Bio jumps into phase 2 with $260M deal for thymus-targeting fusion proteinTolerance Bio has vaulted into the clinic by agreeing to pay NeoImmuneTech up to $260 million for rights to a fusion protein in certain thymus-related indications in the Americas and Europe.fiercebiotech · 1d ago
- STAT+: Moderna launches early trial of Ebola mRNA vaccineNovo and Lilly earnings are out, Aurora Therapeutics slashing staff, and more biotech news from The Readoutstat · 15d ago
- A PureTech startup banks $180M for a new IPF drugCelea, backed by investors such as RA Capital and Leaps by Bayer, is making what it says is an improved version of Roche's Esbriet.biopharma_dive · 1mo ago
- Vertex's sickle cell therapy approved for kids; United Therapeutics buys startup🧬 Vertex’s sickle cell gene therapy approved for kids: Casgevy may now be used to treat either sickle cell disease with recurrent vaso-occlusive crises or transfusion-dependent β-thalassemia patie…endpoints · 1mo ago
- BridgeBio gets funding for drug launch; United buys into cell therapyElsewhere, Otsuka’s kidney drug hit the goal of a confirmatory trial and Vertex’s CRISPR sickle cell drug secured expanded approval.biopharma_dive · 1mo ago
- Opinion: Ending animal testing could set back xenotransplantation just as the field is poised for a breakthrough“Innovations like xenotransplantation would never have reached clinical trials without animal experimentation,” writes transplant surgeon Joshua Mezrich.stat · 2mo ago
- STAT+: Novo Nordisk’s less-bad news on its Wegovy pill boosts earnings and share priceVivek Ramaswamy wins GOP primary for Ohio governor, CellCentric raises $220M for myeloma drug, and more biotech newsstat · 3mo ago
- Avalyn, in pursuit of better lung drugs, banks $300M in an IPOThe biotech will use the proceeds to develop inhalable versions of therapies already on the market for the “idiopathic” and “progressive” forms of pulmonary fibrosis.biopharma_dive · 3mo ago
Data sources
last refreshed 16m ago
Found something off?
comments(0)
5-min edit window · permanent after that